NIAID Considers Exclusive Patent License to GSK for HIV-Specific Antibody

Summary

The National Institute of Allergy and Infectious Diseases is considering granting an exclusive patent commercialization license to GlaxoSmithKline to develop and commercialize a novel, broad, and highly potent HIV-specific antibody.